Maia Vandyke, MD
Urology · Dallas, TXNPI 1265966717
Payments from drug & device makers
Across 276 payments — averaging $287.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$76K
- Laborie Medical Technologies Corp.$2K
- Coloplast$686
- Medtronic$415
- Convatec Inc.$137
- Antares Pharma, Inc.$91
- plus $288 from 8 others
What the payments were for
- Consulting fees$2,2503%
- Speaking & faculty fees$12,82516%
- Grants$50,00063%
- Travel & lodging$5,5137%
- Food & beverage$8,26610%
- Education$5351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 234 | $75,951 |
| Laborie Medical Technologies Corp. | 4 | $1,820 |
| Coloplast | 12 | $686 |
| Medtronic | 4 | $415 |
| Convatec Inc. | 4 | $137 |
| Antares Pharma, Inc. | 6 | $91 |
| Urogen Pharma, Inc. | 3 | $58 |
| Innovation Technologies Inc | 2 | $49 |
| Tolmar, Inc. | 2 | $41 |
| AVEO Pharmaceuticals, Inc. | 1 | $36 |
| AstraZeneca | 1 | $35 |
| Olympus America Inc. | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$51,633
- AdVance XP$10,739
- AMS 700$5,319
- AMS 700 CXR RTE KIT$2,537
- GENERAL - THERAPIES$1,281
- Optilume Urethral Drug Coated Balloon$900
- TACTRA$450
- TITAN$432
- INTERSTIM$279
- AMS 800 Artificial Urinary Sphincter$124
How this compares
$79,388 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 11 | $6,895 |
| Solifenacin Succinate | 12 | $223 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $127 |
| Tamsulosin Hcl | 13 | $98 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $58 |
| Ciprofloxacin Hcl | 13 | $18 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $16 |
Paid to pharmacies, not to this prescriber.
Other urology in Dallas
- Homa PorterDallas$1.8M
- Vitaly MargulisDallas$1.8M
- Solomon WolduDallas$1.2M
- James CochranDallas$1.1M
- Yair LotanDallas$1.1M
- Allen MoreyDallas$1M
- Claus RoehrbornDallas$292K
- Brett JohnsonDallas$175K
- Pat FulghamDallas$174K
- Gregory ThoresonDallas$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.